News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx to Hold Fourth Quarter 2017 Financial Results Conference Call on Friday, March 9, 2018
MOUNTAIN VIEW, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), today announced that the Company's fourth quarter 2017 financial results will be released before market open on Friday, March 9, 2018 . ChemoCentryx executive management will host a conference call
View HTML
Toggle Summary ChemoCentryx Announces Positive Overall Survival Results with CCR2 Inhibitor CCX872 for Locally Advanced/Metastatic Pancreatic Cancer
-- CCX872 plus FOLFIRINOX resulted in overall survival of 29 percent at 18 months in all patients --  -- Clinical findings to be presented at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium -- MOUNTAIN VIEW, Calif. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc.
View HTML
Toggle Summary ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer
MOUNTAIN VIEW, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced the appointment of William (Bill) Fairey as Executive Vice President and
View HTML
Toggle Summary ChemoCentryx Secures up to $100 Million in New Capital Commitments
-- ChemoCentryx to Receive $50 Million Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis -- -- Company Also Enters into $50 Million Growth Capital Financing Agreement with Hercules Capital -- MOUNTAIN
View HTML
Toggle Summary Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney Health Alliance ChemoCentryx to receive regulatory milestone payment from VFMCRP VIFOR FRESENIUS MEDICAL
View HTML
Toggle Summary ChemoCentryx to Present at the 36th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer,
View HTML
Toggle Summary ChemoCentryx to Participate at the Piper Jaffray 29th Annual Healthcare Conference
MOUNTAIN VIEW, Calif. , Nov. 17, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall , Ph.D., President and Chief Executive Officer,
View HTML
Toggle Summary ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights
-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 -- -- Patient enrollment ongoing in registration-supporting trial for avacopan in the treatment C3 Glomerulopathy (C3G) -- -- Plan to launch registration-supporting trial for CCX140 in the treatment of Focal
View HTML
Toggle Summary Presentations at ASN Kidney Week 2017 Highlight ChemoCentryx Platform in Treatment of Kidney Diseases ANCA-Associated Vasculitis and Focal Segmental Glomerulosclerosis (FSGS)
-- Rapid reduction in kidney inflammation following avacopan treatment in patients with ANCA-Associated Vasculitis revealed by analysis of markers of kidney damage -- -- Podocyte protection demonstrated with CCR2 inhibitor CCX140, supporting differentiated potential treatment option for patients
View HTML
Toggle Summary ChemoCentryx to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 7, 2017
MOUNTAIN VIEW, Calif. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's third quarter 2017 financial results will be released
View HTML